Applied Molecular Transport

NasdaqGS:AMTI Stock Report

Mkt Cap: US$39.7m

We’ve recently updated our valuation analysis.

Applied Molecular Transport Valuation

Is AMTI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for AMTI?

Other financial metrics that can be useful for relative valuation.

AMTI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.002x
PEG Ration/a

Price to Book Ratio vs Peers

How does AMTI's PB Ratio compare to its peers?

The above table shows the PB ratio for AMTI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.6x
INAB IN8bio
1.3xn/aUS$39.7m
AVRO AVROBIO
0.4x-0.1%US$39.3m
NXTC NextCure
0.2x-13.2%US$40.3m
TARA Protara Therapeutics
0.3x41.7%US$40.8m
AMTI Applied Molecular Transport
0.5x-1.0%US$39.7m

Price-To-Book vs Peers: AMTI is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (0.6x).


Price to Earnings Ratio vs Industry

How does AMTI's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a9.4%
n/an/an/a

Price-To-Book vs Industry: AMTI is good value based on its Price-To-Book Ratio (0.5x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is AMTI's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

AMTI PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate AMTI's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of AMTI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate AMTI's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate AMTI's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst AMTI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.02
US$10.45
+924.5%
76.4%US$21.00US$0.80n/a4
Nov ’23US$0.89
US$12.25
+1,270.2%
72.0%US$21.00US$2.00n/a4
Oct ’23US$0.97
US$11.88
+1,120.7%
66.7%US$21.00US$2.00n/a5
Sep ’23US$1.36
US$11.88
+773.5%
66.7%US$21.00US$2.00n/a5
Aug ’23US$1.77
US$12.00
+578.0%
64.8%US$21.00US$2.60n/a5
Jul ’23US$2.90
US$23.68
+716.6%
61.9%US$50.00US$10.00n/a5
Jun ’23US$2.97
US$33.08
+1,013.8%
75.9%US$74.00US$10.00n/a5
May ’23US$4.29
US$58.88
+1,272.5%
46.0%US$86.00US$10.40n/a5
Apr ’23US$7.64
US$70.25
+819.5%
21.0%US$86.00US$46.00n/a4
Mar ’23US$6.12
US$73.00
+1,092.8%
14.2%US$86.00US$57.00n/a4
Feb ’23US$10.14
US$73.00
+619.9%
14.2%US$86.00US$57.00n/a4
Jan ’23US$13.98
US$75.75
+441.8%
8.6%US$86.00US$68.00n/a4
Dec ’22US$16.35
US$75.75
+363.3%
8.6%US$86.00US$68.00n/a4
Nov ’22US$23.60
US$75.75
+221.0%
8.6%US$86.00US$68.00US$0.894
Oct ’22US$26.05
US$75.75
+190.8%
8.6%US$86.00US$68.00US$0.974
Sep ’22US$31.11
US$75.75
+143.5%
8.6%US$86.00US$68.00US$1.364
Aug ’22US$28.03
US$75.75
+170.2%
8.6%US$86.00US$68.00US$1.774
Jul ’22US$46.61
US$75.75
+62.5%
8.6%US$86.00US$68.00US$2.904
Jun ’22US$46.03
US$75.75
+64.6%
8.6%US$86.00US$68.00US$2.974
May ’22US$57.49
US$77.25
+34.4%
11.6%US$92.00US$68.00US$4.294
Apr ’22US$63.57
US$80.33
+26.4%
10.3%US$92.00US$74.00US$7.643
Mar ’22US$56.61
US$48.67
-14.0%
37.0%US$74.00US$34.00US$6.123
Feb ’22US$35.62
US$34.67
-2.7%
7.2%US$38.00US$32.00US$10.143
Jan ’22US$30.77
US$34.67
+12.7%
7.2%US$38.00US$32.00US$13.983
Dec ’21US$32.75
US$34.67
+5.9%
7.2%US$38.00US$32.00US$16.353
Nov ’21US$29.39
US$34.67
+18.0%
7.2%US$38.00US$32.00US$23.603

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies